Barbara K. Burton

13.1k total citations · 1 hit paper
248 papers, 7.7k citations indexed

About

Barbara K. Burton is a scholar working on Physiology, Clinical Biochemistry and Molecular Biology. According to data from OpenAlex, Barbara K. Burton has authored 248 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Physiology, 78 papers in Clinical Biochemistry and 73 papers in Molecular Biology. Recurrent topics in Barbara K. Burton's work include Lysosomal Storage Disorders Research (88 papers), Metabolism and Genetic Disorders (77 papers) and Trypanosoma species research and implications (34 papers). Barbara K. Burton is often cited by papers focused on Lysosomal Storage Disorders Research (88 papers), Metabolism and Genetic Disorders (77 papers) and Trypanosoma species research and implications (34 papers). Barbara K. Burton collaborates with scholars based in United States, United Kingdom and Canada. Barbara K. Burton's co-authors include Jerry Vockley, Roberto Giugliani, Laurence I. Burd, Brad Angle, Paul Harmatz, John J. Mitchell, Henry L. Nadler, Nicola Longo, Simon Jones and Robert G. Dillard and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Genetics.

In The Last Decade

Barbara K. Burton

238 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phenylalanine hydroxylase deficiency: diagnosis and management guideline

2014 465 citations Jerry Vockley, Barbara K. Burton et al. Genetics in Medicine profile →

Peers

Countries citing papers authored by Barbara K. Burton

Since Specialization

Citations

This map shows the geographic impact of Barbara K. Burton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara K. Burton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara K. Burton more than expected).

Fields of papers citing papers by Barbara K. Burton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara K. Burton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara K. Burton. The network helps show where Barbara K. Burton may publish in the future.

Co-authorship network of co-authors of Barbara K. Burton

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara K. Burton. A scholar is included among the top collaborators of Barbara K. Burton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara K. Burton. Barbara K. Burton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II 2025 ·New England Journal of Medicine ·(unknown), Barbara K. Burton, (unknown), Deepa Rajan, Simon A. Jones, (unknown), (unknown), Akhil Bhalla, (unknown), (unknown), (unknown), Fabian Model, Ryan J. Watts, Matthew D. Troyer, Peter Chin, Carole Ho	0
2	Genotype–phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey 2024 ·Molecular Genetics and Metabolism ·Joseph Muenzer, Hernán Amartino, Barbara K. Burton, (unknown), Anna Tylki‐Szymańska, (unknown), Jaco Botha, (unknown), David Merberg, Madhusudan Natarajan, David Whiteman, Roberto Giugliani	2
3	Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG) 2024 ·Genetics in Medicine ·Wendy E. Smith, Susan A. Berry, (unknown), Christine Brown, Barbara K. Burton, (unknown), (unknown), Jennifer Malinowski, Kim L. McBride, (unknown), Curt Scharfe, Jerry Vockley	10
4	Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐ IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II 2024 ·Journal of Inherited Metabolic Disease ·Joseph Muenzer, Barbara K. Burton, Paul Harmatz, (unknown), Matilde Ruíz-Garcìa, Simon Jones, Nathalie Guffon, Michal Inbar‐Feigenberg, Drago Bratkovic, Stewart Rust, (unknown), (unknown), Karen S. Yee, David Whiteman, (unknown)	1
5	Newborn screening for mucopolysaccharidosis type II: Lessons learned 2023 ·Molecular Genetics and Metabolism ·Barbara K. Burton, Vera P. Shively, (unknown), (unknown), Jennifer Kirsty Burton, Dorothy K. Grange, Katherine Christensen, (unknown), (unknown), (unknown), Khaja Basheeruddin	6
6	Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study 2023 ·Orphanet Journal of Rare Diseases ·Joseph Muenzer, Barbara K. Burton, Hernán Amartino, Paul Harmatz, Luis González Gutiérrez-Solana, Matilde Ruíz-Garcìa, (unknown), David Merberg, (unknown), Simon Jones	3
7	A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials 2021 ·Molecular Genetics and Metabolism Reports ·Barbara K. Burton, Anne Skalicky, Christoph Baerwald, Deborah A. Bilder, Cary O. Harding, Aaron B. Ilan, Elaina Jurecki, Nicola Longo, David T. Madden, Serap Sivri, Gisela Wilcox, Janet A. Thomas, Kathleen Delaney	3
8	Executive function in phenylketonuria (PKU): Insights from the Behavior Rating Inventory of Executive Function (BRIEF) and a large sample of individuals with PKU. 2020 ·Neuropsychology ·Shawn E. Christ, (unknown), Barbara K. Burton, Mitzie Grant, Susan E. Waisbren, (unknown), Deborah A. Bilder, Desirée A. White, (unknown)	12
9	Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial 2018 ·PMC ·Cary O. Harding, Roberto Amato, (unknown), Nicola Longo, Barbara K. Burton, John Posner, Haoling H. Weng, Markus Meriläinen, (unknown), Joy Jiang, Jerry Vockley	1
10	Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment 2015 ·SHILAP Revista de lepidopterología ·Christian J. Hendriksz, Joseph Muenzer, Adeline Vanderver, Jonathan M. Davis, Barbara K. Burton, Nancy J. Mendelsohn, Nan Wang, Luying Pan, Arian Pano, Ann Barbier	27
11	Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial 2014 ·The Lancet ·Nicola Longo, Cary O. Harding, Barbara K. Burton, Dorothy K. Grange, Jerry Vockley, Melissa Wasserstein, Gregory M. Rice, Alejandro Dorenbaum, Jutta K. Neuenburg, Donald G. Musson, (unknown), Saba Sile	126
12	A multinational, multidisciplinary consensus for the diagnosis and management of spinal cord compression among patients with mucopolysaccharidosis VI 2012 ·Molecular Genetics and Metabolism ·Guirish A. Solanki, Tord D. Alden, Barbara K. Burton, Roberto Giugliani, Dafne Dain Gandelman Horovitz, Simon Jones, Christina Lampe, Kenneth W. Martin, Maura E. Ryan, (unknown), (unknown), Klane K. White, Paul Harmatz	30
13	Psychiatric symptoms in adults with phenylketonuria 2012 ·Molecular Genetics and Metabolism ·Deborah A. Bilder, Barbara K. Burton, Hilary Coon, (unknown), (unknown), (unknown), (unknown), Amanda V. Bakian, Nicola Longo	52
14	Congenital malformations : evidence-based evaluation and management 2008 ·Andalas University Repository (Andalas University) ·Praveen Kumar, Barbara K. Burton	24
15	Neuroimaging findings in children with rare or novel de novo chromosomal anomalies 2008 ·Birth Defects Research Part A Clinical and Molecular Teratology ·Leon G. Epstein, Ali Jalali, (unknown), (unknown), Joshua V. Ross, Justine Coppinger, Katrin M. Carlson, Joel Charrow, Barbara K. Burton, Donald Zimmerman, John S. Curran, (unknown), (unknown), Delilah Burrowes, Brad Angle, Cynthia V. Stack, Lisa G. Shaffer, John A. Kessler, Alexander G. Bassuk	1
16	Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome 2005 ·Genetics in Medicine ·Satkiran S. Grewal, Robert Wynn, José E. Abdenur, Barbara K. Burton, Maged I. Gharib, Claudia M. Haase, Robert J. Hayashi, Shalini Shenoy, David Sillence, George E. Tiller, (unknown), Annet van Royen‐Kerkhof, J. E. Wraith, Paul Woodard, Guy Young, Nico Wulffraat, Chester B. Whitley, Charles Peters	74
17	UREA CYCLE DISORDERS 2000 ·Clinics in Liver Disease ·Barbara K. Burton	32
18	Microcephaly, lymphedema, and chorioretinal dysplasia: Report of two additional cases 1994 ·American Journal of Medical Genetics ·Brad Angle, (unknown), Barbara K. Burton, Marilyn T. Miller, Michael J. Shapiro, John M. Opitz	13
19	A new skeletal dysplasia: Clinical, radiologic, and pathologic findings 1986 ·The Journal of Pediatrics ·Barbara K. Burton, Thomas E. Sumner, Leonard O. Langer, David L. Rimoin, G. Adomian, Ralph S. Lachman, (unknown), David L. Kelly, Richard G. Weaver	10
20	Hyperpipecolic acidemia: Clinical and biochemical observations in two male siblings 1981 ·The Journal of Pediatrics ·Barbara K. Burton, (unknown), (unknown)	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact